Laboratorios Rovi : Q3 EBITDA notably above. Outlook revised upwards again
>Surprisingly strong CMO helps Rovi deliver double-digit sales growth in Q3 - Group sales grew +10% y-o-y in Q3 2023, reaching € 215m, ahead of our estimates (4pp) and the consensus (4pp), and posting a 8pp sequential improvement which is remarkable given the weak momentum of Covid vaccine sales and the hard comps in heparins. This beat is due to a counter-intuitive surge in toll manufacturing sales to Moderna for its mRNA Covid vaccine related to the preparation of i...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.